These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 34768993)

  • 21. Programmed Cell Death 1 Ligand 1 and Programmed Cell Death 1 Ligand 2 Are Expressed in Conjunctival Invasive Squamous Cell Carcinoma: Therapeutic Implications.
    Wolkow N; Jakobiec FA; Afrogheh AH; Eagle RC; Pai SI; Faquin WC
    Am J Ophthalmol; 2019 Apr; 200():226-241. PubMed ID: 30633894
    [TBL] [Abstract][Full Text] [Related]  

  • 22. PD-L1 and PD-L2 Expression in Cervical Cancer: Regulation and Biomarker Potential.
    Rotman J; den Otter LAS; Bleeker MCG; Samuels SS; Heeren AM; Roemer MGM; Kenter GG; Zijlmans HJMAA; van Trommel NE; de Gruijl TD; Jordanova ES
    Front Immunol; 2020; 11():596825. PubMed ID: 33424844
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of Primary Systemic Therapy on PD-1, PD-L1, and PD-L2 mRNA Expression in Advanced Breast Cancer.
    Karsono R; Azhar MA; Pratiwi Y; Saputra F; Nadliroh S; Aryandono T
    Asian Pac J Cancer Prev; 2021 Jul; 22(7):2069-2077. PubMed ID: 34319029
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Increased both PD-L1 and PD-L2 expressions on monocytes of patients with hepatocellular carcinoma was associated with a poor prognosis.
    Yasuoka H; Asai A; Ohama H; Tsuchimoto Y; Fukunishi S; Higuchi K
    Sci Rep; 2020 Jun; 10(1):10377. PubMed ID: 32587357
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Programmed death ligand-1 over-expression correlates with malignancy and contributes to immune regulation in ovarian cancer.
    Maine CJ; Aziz NH; Chatterjee J; Hayford C; Brewig N; Whilding L; George AJ; Ghaem-Maghami S
    Cancer Immunol Immunother; 2014 Mar; 63(3):215-24. PubMed ID: 24297569
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Human brain endothelial cells endeavor to immunoregulate CD8 T cells via PD-1 ligand expression in multiple sclerosis.
    Pittet CL; Newcombe J; Prat A; Arbour N
    J Neuroinflammation; 2011 Nov; 8():155. PubMed ID: 22067141
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immune microenvironment and evasion mechanisms in adenoid cystic carcinomas of salivary glands.
    Mosconi C; de Arruda JAA; de Farias ACR; Oliveira GAQ; de Paula HM; Fonseca FP; Mesquita RA; Silva TA; Mendonça EF; Batista AC
    Oral Oncol; 2019 Jan; 88():95-101. PubMed ID: 30616805
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The expression of programed death ligand-1 could be related with unfavorable prognosis in salivary duct carcinoma.
    Sato F; Akiba J; Kawahara A; Naito Y; Ono T; Takase Y; Murata K; Abe H; Yamaguchi T; Miyoshi H; Abe Y; Mihara Y; Tanikawa M; Akashi M; Kurose H; Umeno H; Yano H
    J Oral Pathol Med; 2018 Aug; 47(7):683-690. PubMed ID: 29719073
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Profiles of PD-1, PD-L1, PD-L2 in Gastric Cancer and Their Relation with Mutation, Immune Infiltration, and Survival.
    Liu J; Li H; Sun L; Yuan Y; Xing C
    Biomed Res Int; 2020; 2020():2496582. PubMed ID: 32596285
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Negative influence of programmed death-1-ligands on the survival of esophageal cancer patients treated with chemotherapy.
    Tanaka K; Miyata H; Sugimura K; Kanemura T; Hamada-Uematsu M; Mizote Y; Yamasaki M; Wada H; Nakajima K; Takiguchi S; Mori M; Doki Y; Tahara H
    Cancer Sci; 2016 Jun; 107(6):726-33. PubMed ID: 27015293
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Stratification of ovarian tumor pathology by expression of programmed cell death-1 (PD-1) and PD-ligand- 1 (PD-L1) in ovarian cancer.
    Drakes ML; Mehrotra S; Aldulescu M; Potkul RK; Liu Y; Grisoli A; Joyce C; O'Brien TE; Stack MS; Stiff PJ
    J Ovarian Res; 2018 May; 11(1):43. PubMed ID: 29843813
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Overexpression of PD-L1 and PD-L2 Is Associated with Poor Prognosis in Patients with Hepatocellular Carcinoma.
    Jung HI; Jeong D; Ji S; Ahn TS; Bae SH; Chin S; Chung JC; Kim HC; Lee MS; Baek MJ
    Cancer Res Treat; 2017 Jan; 49(1):246-254. PubMed ID: 27456947
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Upregulation of PD-L1 and PD-L2 in neck node metastases of head and neck squamous cell carcinoma.
    Moratin J; Metzger K; Safaltin A; Herpel E; Hoffmann J; Freier K; Hess J; Horn D
    Head Neck; 2019 Aug; 41(8):2484-2491. PubMed ID: 30821864
    [TBL] [Abstract][Full Text] [Related]  

  • 34. High levels of the soluble programmed death-ligand (sPD-L1) identify hepatocellular carcinoma patients with a poor prognosis.
    Finkelmeier F; Canli Ö; Tal A; Pleli T; Trojan J; Schmidt M; Kronenberger B; Zeuzem S; Piiper A; Greten FR; Waidmann O
    Eur J Cancer; 2016 May; 59():152-159. PubMed ID: 27039170
    [TBL] [Abstract][Full Text] [Related]  

  • 35. PD-L1/L2 protein levels rapidly increase on monocytes via trogocytosis from tumor cells in classical Hodgkin lymphoma.
    Kawashima M; Carreras J; Higuchi H; Kotaki R; Hoshina T; Okuyama K; Suzuki N; Kakizaki M; Miyatake Y; Ando K; Nakayama M; Umezu S; Horie R; Higuchi Y; Katagiri K; Goyama S; Kitamura T; Chamoto K; Yano S; Nakamura N; Kotani A
    Leukemia; 2020 Sep; 34(9):2405-2417. PubMed ID: 32089543
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Associations of PD-L1, PD-L2, and HLA class I expression with responses to immunotherapy in patients with advanced sarcoma: post hoc analysis of a phase 1/2 trial.
    Miwa S; Nojima T; Alomesen AA; Ikeda H; Yamamoto N; Nishida H; Hayashi K; Takeuchi A; Igarashi K; Higuchi T; Yonezawa H; Araki Y; Morinaga S; Asano Y; Tsuchiya H
    Clin Transl Oncol; 2021 Aug; 23(8):1620-1629. PubMed ID: 33635466
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cerebrospinal fluid soluble programmed death-ligand 1 is a useful prognostic biomarker in primary central nervous system lymphoma.
    Cheng CL; Yao CY; Huang PH; Yu CW; Fang WQ; Chuang WH; Wu SJ; Lin YJ; Hung YC; Tsai CH; Yu SC; Chou WC; Tien HF
    Br J Haematol; 2023 Apr; 201(1):75-85. PubMed ID: 36480431
    [TBL] [Abstract][Full Text] [Related]  

  • 38. High plasma levels of soluble programmed cell death ligand 1 are prognostic for reduced survival in advanced lung cancer.
    Okuma Y; Hosomi Y; Nakahara Y; Watanabe K; Sagawa Y; Homma S
    Lung Cancer; 2017 Feb; 104():1-6. PubMed ID: 28212990
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prognostic significance of PD-1 and PD-L1 positive tumor-infiltrating immune cells in ovarian carcinoma.
    Buderath P; Mairinger F; Mairinger E; Böhm K; Mach P; Schmid KW; Kimmig R; Kasimir-Bauer S; Bankfalvi A; Westerwick D; Hager T
    Int J Gynecol Cancer; 2019 Nov; 29(9):1389-1395. PubMed ID: 31492714
    [TBL] [Abstract][Full Text] [Related]  

  • 40. PD-1, PD-L1, PD-L2 expression in the chordoma microenvironment.
    Mathios D; Ruzevick J; Jackson CM; Xu H; Shah SR; Taube JM; Burger PC; McCarthy EF; Quinones-Hinojosa A; Pardoll DM; Lim M
    J Neurooncol; 2015 Jan; 121(2):251-9. PubMed ID: 25349132
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.